Atossa Therapeutics, Inc. (ATOS)

NASDAQ: ATOS · IEX Real-Time Price · USD

1.420

-0.040 (-2.74%)

At close: May 28, 2024, 4:00 PM

1.440

+0.020 (1.41%)

After-hours: May 28, 2024, 7:47 PM EDT

Atossa Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2010
Selling, General & Admin	14.04	12.61	11.31	8	10.62	Upgrade
Research & Development	17.33	15.08	9.21	6.61	6.65	Upgrade
Operating Expenses	31.38	27.69	20.52	14.61	17.27	Upgrade
Operating Income	-31.38	-27.69	-20.52	-14.61	-17.27	Upgrade
Other Expense / Income	-1.28	-0.73	0.09	3.22	-0.03	Upgrade
Pretax Income	-30.09	-26.96	-20.61	-17.83	-17.24	Upgrade
Net Income	-30.09	-26.96	-20.61	-17.83	-17.24	Upgrade
Preferred Dividends	0	0	0	4.5	0	Upgrade
Net Income Common	-30.09	-26.96	-20.61	-22.33	-17.24	Upgrade
Shares Outstanding (Basic)	126	127	117	11	8	Upgrade
Shares Outstanding (Diluted)	126	127	117	11	8	Upgrade
Shares Change	-0.43%	8.27%	934.13%	33.09%	104.36%	Upgrade
EPS (Basic)	-0.24	-0.21	-0.18	-1.97	-2.03	Upgrade
EPS (Diluted)	-0.24	-0.21	-0.18	-1.97	-2.03	Upgrade
Free Cash Flow	-20.96	-20.79	-16.48	-11.58	-9.14	Upgrade
Free Cash Flow Per Share	-0.17	-0.16	-0.14	-1.02	-1.07	Upgrade
EBITDA	-30.07	-26.95	-20.58	-17.78	-17.19	Upgrade
Depreciation & Amortization	0.02	0.01	0.02	0.05	0.05	Upgrade
EBIT	-30.09	-26.96	-20.61	-17.83	-17.24	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).